On Thursday, Fate Therapeutics announced it terminated a 2020 collaboration agreement with Johnson & Johnson’s biopharma subsidiary Janssen. In response, the next-generation cell therapy company’s stock sank by 54% in pre-market trading Friday.
Featured Posts
Biotech behemoth Amgen inked a licensing agreement Thursday with Netherlands-based Synaffix for the development of next-generation antibody-drug conjugates.
Moderna entered into a collaboration/licensing agreement Thursday with oncology-focused CytomX to discover and develop conditionally activated mRNA therapies for cancer.
Germany’s CureVac AG said on Friday its second-generation COVID-19 vaccine produced virus-neutralizing antibodies against the BA.1 subvariant of Omicron, based on preliminary data from an early-stage trial.
The European Commission said on Friday it approved delaying the deadline for companies to comply with a new law regulating medical devices in order to prevent shortages of lifesaving equipment.
Pfizer Inc. is exploring options for some early-stage treatments for rare diseases and cancer in a bid to focus on “high-impact” medicines and vaccines, the company said on Thursday.
China gave a presentation on its COVID-19 situation in an online meeting with the World Health Organization and its member states, China’s national health commission and diplomats said on Thursday, as it seeks to fend off criticism about its recent reporting on the outbreak.
A letter published Wednesday in the NEJM links a stroke patient’s death to lecanemab. Eisai investigators respond.
JP Morgan week is shaping up to approximate pre-pandemic attendance levels as executives return to San Francisco after two years of COVID-19-enforced absences.